The EPLC and Swiss HLG are delighted to invite you to the 14th International Pharmaceutical Licensing Symposium; Peak Performance. To be held in Montreux, Switzerland, 19th – 21st September 2018.
This year the EPLC have put together a program with the theme of Peak Performance designed to help you evolve your deal making in an ever-changing Business Development environment.
Why you should register
Who should attend
Business Development Executives, General Managers, Directors, Owners, Executives in Marketing, Regulatory & Finance from the Healthcare sector, from all countries
Don’t miss out on the early bird discount for the 8th IPLS in Madrid. This offer has been extended until Monday 8th of May, so there’s still time to register at this great price!
Special Offer for Swiss HLG Members
Benefit from an additional €100 discount, if you are one of the first 20 Swiss hLG members to register. Combine this offer with the early bird special and pay only €775 for this 2-day event. Please highlight that you are entitled to the Swiss HLG offer on your registration for.
Not yet a member? Find out why it’s worth joining us!
Dates: Thursday 28th September to Friday 29th September 2017
Early Bird Price: €875.00
Normal Price: €1025.00.
(Early Bird Price available until 8th May 2017)
While registration has only been open for a few weeks, the conference is filling fast, with a quarter of all places already reserved! This exciting conference has a new feature – the start-up pitches. These will provide a great opportunity to find out about the innovation occurring in Switzerland, as well as what is needed to make it as a start-up and what’s involved in successfully financing your venture.
“Challenges in Financing Life Science Ventures”, will give participants the opportunity to connect with start-up friendly organisations, such as Inartis, BioAlps and VentureLab as well as providing opportunities to gain expert insights from start-up founders, including Geneuro, that have already paved the way with their IPO journeys.
Big Pharma will be there too. You’ll hear from both VC and BD&L functions, who will explain their financial language differences, helping you to know how to approach the right organisation at the right time!
We haven’t forgotten the importance of networking, and as with any Swiss HLG event, there will be plenty of opportunities for you to connect with speakers and attendees. If you are a Swiss HLG Member, we’ve taken this a step further by arranging a member’s only evening on the 13th of June, where you will have the exclusive opportunity to meet the speakers, organisers and sponsors of the Summer Conference, before the crowds arrive.
This exciting one-day conference will be held on June 15, 2017, at the Aquatis Hotel, Lausanne. For members of Swiss HLG, stay tuned! Invitations to our members only event, to be held on the evening of the 14th of June, will be sent out shortly.
Please download the attached Summer Conference Flyer, where you will find all the links and information necessary for registration, discounted hotel reservations, full program and speaker details.
We look forward to seeing you there.
Conference Director & Board Member, Swiss HLG
Swiss HLG and BaselArea.swiss are excited to present the Swiss HLG’s latest start-up workshop collaboration. We will explore the value of science vs. the value of cash in the valuation of a Biotech company.The risk-adjusted, net present value (rNPV) method is the standard valuation method used within pharma and biotech companies when valuing assets beyond discovery stage.
This approach depicts the drug/pipeline development plan, using R&D costs & timeline, success rates and peak sales potential.The quantity of available information in the pharmaceutical area enables us to determine and provide benchmarks for these assumptions. Well-calibrated, the rNPV method is thus a powerful tool to build, challenge and value the company’s strategy. It also shows how the value of the company develops as it reaches various milestones. Is it, however, enough for investors?
From an investor’s perspective, it is crucial to understand how long it will take before they can exit and what is the potential for ROI (Return on Investment)? They need to figure out the conditions necessary to harvest their investment and anticipate the multiple later-round investors and incentive packages required for key employees, that may otherwise, dilute their stake. While rNPV highlights the roadmap for the companies ‘scientific bet’, it is the VC method that is the roadmap for the cash investment.
The purpose of this workshop is to decrypt the reasons behind using rNPV or VC methodologies to value a Biotech company. With the support of interactive cases, the participants will learn how Biotech companies can better anticipate the VCs’ point of view when presenting their valuation work.
Wednesday, March 29th, 2017
Technology Park Basel
(Hochbergstrasse 60C, 4057 Basel)
16:00 – Introduction by Stephan Emmerth, BaselArea.swiss
16:05 – Introduction by Zaki Sellam, Swiss HLG
16:10 – Marie Petit, Villiger Valuation
18:00 – Apero
Participation is free of charge, but seats are limited.
To register, please email: Stephan.firstname.lastname@example.org
Registration is compulsory and subjected to validation. Priority is given to people with founded start-ups or concrete projects.
We look forward to meeting you there.
The aim of the conference is to establish high-quality networking among the Swiss Romand healthcare companies, including start-ups, medium and large pharma, life science, biotech and other hybrids of healthcare-centric players. There is also the opportunity for selected companies to increase visibility through conducting an elevator pitch of their innovation.
To express your interest in attending, please send an email to email@example.com, and we will send you the registration details, as soon as they are confirmed.
We kick-started Sunday with a 2-hour workshop, presented by the dynamic and experienced Monika Naef, Certified Global Negotiator and Partner at DUFOUR Attorneys. In this session, delegates were able to gain hands-on experience, negotiating their way out of “An Agreement Gone Sour”.
Over coffee, delegates could network with new colleagues and catch up with old friends before the official welcome and opening of the conference was given by Gabrielle Gache, President of Swiss HLG.
Thomas Szucs, Chairman of the Board for Helsana Health Insurance, captured the audience with his opening keynote speech – “Developing New Medicines in a Time of Cost Containment“.
This was followed by a presentation on “Healthcare Trends and their Impact on Corporate Transactions”, given by Dominik Hotz, Partner, PricewaterhouseCoopers.
To finish the day’s speakers, Marc Churin, HR Manager Switzerland, for Samsic, gave a lively and interactive personal development session on the “Use of Social Media, Beyond Business Networking”. He showed delegates the many benefits of being a dedicated LinkedIn user, creating synergies and how to reach anyone, in any company, worldwide, within 5 minutes!
In the evening, everyone enjoyed a finger food, buffet dinner, with options to dine inside or out. Great opportunities to network in a relaxed atmosphere, combined with eating warm soup and food prepared over the fire were a big hit among the delegates!
The Swiss HLG Winter Conference aims to inspire and inform. Here is a glimpse of just a few of our upcoming outstanding speakers. They will share their insights on Healthcare Megatrends and the impacts they will have on our business models and deal structures.
Key Note Speakers and confirmed speakers
Michel L. Pettigrew
President of the Executive Board and Chief Operating Officer, Ferring Pharmaceuticals
Chairman of the Board, Helsana
Global Head of Strategic Partnering, Roche
The Program will be complemented by a Personal Development Session on Networking run by Marc Churin, HR Manager at Samsic Swiss and a Pre-Conference Workshop “War of the Roses – Negotiating your way out,” by Monika Naef, Lawyer, Dufour Attorneys and Notary Public.
What will we be talking about?
You can look forward hearing speakers share their knowledge and insights in the following areas of Healthcare Megatrends:
Demographic and Economic Perspectives
The Globalization Perspective
The Life Sciences – Bio-Entrepreneur, Investor and Patient Perspectives
Information Technology Megatrends
Megatrends and their Impact on Deal Structures
We will also be celebrating our 15th Jubilee. We look forward to having you join us for some stimulating and healthy debates and plenty of Swiss HLG fireside chats, and celebrations!
With registration dates confirmed, key-note speakers hand-picked and exciting topics chosen, don’t forget to block out your calendar from the 29th-31st of January. Combine this exciting conference with our 15th-anniversary celebration at the beautiful Jugendstilhotel Paxmontana in Flueli-Ranft, near Lucerne.
Read on to find out more about what the Swiss HLG Winter Conference has in store for you.
Megatrends are sustained, global, social, economic, political, environmental or technological changes. They are here to stay and will make a considerable and durable impact on the healthcare environment by creating new opportunities, challenges and risks for our businesses.
The Swiss HLG 2017 Winter Conference, has invited renowned specialists from the pharma, healthcare, information technology, finance, insurance and academic worlds to address this theme. Along with other topics, they will review and discuss the implications of the following Megatrends:
The presenters will challenge our present assumptions by sharing their insights on these Megatrends and the impacts on our business models and deal structures in the foreseeable future. There will also be exciting open panel discussions, where input from all participants will be welcome, to better define, describe and address these upcoming challenges.
Stay tuned for more information. For highlights from the 2016 Winter Conference, held at the same stunning venue, click here
Come a day early to the 8th EPLS in Brussels, on Wednesday 21st September, and get involved in a great new initiative, co-organised by EPLS and Europharm SMC! They have established an exciting afternoon of B2B, One-to-One business meetings, which will be held at the Radisson Blue Royal Hotel, Brussels.
These B2B meetings will be a great opportunity for HLG/PLG and Europharm SMC members to meet, network and to do business. Full details of how to register can be seen at the Europharma website
Don’t forget to register for the 8th EPLS in Brussels. A summary of the conference is below, and you can follow the links for registration and more information.
Swiss HLG Member Discount – Provide your Swiss HLG Member number when you register and receive an extra 100 euros discount.
This year the Executive Committee have once again put together an exciting programme of presentations and social events. The two-day event will feature 5 sessions with presentations, case studies and a panel discussion on different aspects of the industry covering: Strategic Issues, Deal Finances & Valuation, Biosimilars / Generics, Panel Discussion – European Market Access (with representation from France, Germany, Italy, Spain and the UK) and Patient Centricity / Digital health.
Take the opportunity to hear about the next level of Swiss HLG’s Good Partnering Practices (GPP) Initiative on Friday morning.
The main gala dinner will be held on Thursday evening at the elegant Théatre du Vaudeville, a 2-minute walk from the Radisson Blue Royal Hotel and 1 minute from the Grand Place. This stunning theatre was inaugurated in 1884 and has since been restored to its former Victorian glory. Guests will be welcomed with a networking drinks reception before dinner is served in the Theatre.
For details on the conference program and venue, please visit the PLG Website.
The Swiss HLG board looks forward to meeting you there!
This workshop will show how emerging healthcare start-ups can expedite growth through partnering and without equity dilution. It will address the key steps, opportunities, bottlenecks and challenges in partnering. It is intended for entrepreneurs, people wishing to start a healthcare company as well as emerging companies’ CEO/business development executives that wish to understand the basic practices of project valuation, negotiation, and partnering. Focus will be on partnering R&D technologies as well as pre-clinical and clinical – stage assets.
Besides theory, most of the seminar will be very practical work on case studies and attendees are invited to submit cases to be discussed during the event.
The workshop, which will be held on April 27th, 2016, location to be determined, is organized by the Swiss HLG, a society dedicated to best practices in licensing and business development, together with i-net.
|15:00||Welcome & introduction to Swiss HLG and i-net – Gabrielle Gache, president Swiss HLG; Zaki Sellam, board member Swiss HLG; Stephan Emmerth, i-net|
|15:15||Emerging company perspective – Helmut Kessmann (Polyphor, T3 Pharma)|
Big Pharma / corporate VC perspective – Markus Goebel (Novartis Venture Fund)
|17:30||Practical work – case studies|
|19:00||Apero and Networking|
The participation at the event is free of charge, but seats are limited. Please note that registration via email to firstname.lastname@example.org is compulsory and subject to validation. Priority will be given to people with concrete projects and or those from already founded healthcare start-ups.
We look forward to meeting you there!
For more information about the program and registrations, fill in the registration form at fenicia-events.eu/plg-hlg